Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allogene Frustrated By FDA’s Delayed CAR-T Trial Review

ALLO-510A Awaits Green Light To Start Phase II Study

Executive Summary

Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”

You may also be interested in...



Trials In Focus: Allogene Off-The-Shelf Study Mirrors Earlier CAR-T Trials

In Scrip’s new column tracking clinical trial developments, NewAmsterdam, CatalYm, Verve, Bellerophon and Almirall announced new trials or changes to existing ones, while CROs Parexel and PPD announced new programs and CTI appointed a new exec.

2seventy/BMS’s Abecma Shines In Earlier Lines, But J&J/Legend’s Carvykti May Have Edge

Without disclosing data, 2seventy and BMS reported positive Phase III results in third-line and beyond multiple myeloma, but Carvykti will soon have second-line data.

Caribou Hit By Familiar Allo CAR-T Durability Problems

Like some of its allo CAR-T rivals, CB-010’s early promise has fallen away, but Caribou still hopes a higher dose can bring with it real durability of response.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel